Double activation and low IL-2 manufacturing protocol increase expansion of healthy and patient-derived CAR-Tregs.

Authors: Ugolini A, Miceli A, Bercher-Brayer C, Cesarano S, Camisa B, Carulli P, Monti P, Ramirez GA, Bonomi E, Rudilosso L, Dagna L, Cesana D, Greco R, Ciceri F, Bonini C, Doglio M

Journal: Molecular therapy. Advances